XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Operating Segment and Related Information (Tables)
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Schedules of Concentration of Risk, by Risk Factor The Company's revenue concentration of 10% and greater are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Segment2021202020212020
Customer AInfrastructure18.9%*12.2%*
Customer BInfrastructure13.0%***
*Less than 10% revenue concentration
Summary of Company's Operating Segments
Summary information with respect to the Company’s operating segments is as follows (in millions):

 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Revenue
Infrastructure
$383.0 $160.8 $776.3 $509.6 
Life Sciences1.6 — 2.8 — 
Spectrum10.2 9.7 31.3 29.3 
Total revenue$394.8 $170.5 $810.4 $538.9 

 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Income (loss) from operations
Infrastructure
$12.6 $6.0 $17.0 $13.1 
Life Sciences(4.9)(4.7)(14.2)(11.4)
Spectrum(1.2)(11.7)(1.0)(15.8)
Other(1.0)(0.4)(1.6)(2.1)
Non-operating Corporate(4.4)(5.3)(17.7)(22.4)
Total income (loss) from operations$1.1 $(16.1)$(17.5)$(38.6)


A reconciliation of the Company's consolidated segment operating income to consolidated earnings before income taxes is as follows (in millions):
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Income (loss) from operations$1.1 $(16.1)$(17.5)$(38.6)
Interest expense(12.8)(17.9)(46.6)(56.2)
Loss on early extinguishment or restructuring of debt(0.1)— (12.5)(9.2)
Loss from equity investees(2.9)(1.3)(4.8)(4.0)
Other income0.6 6.9 4.4 73.0 
Loss from continuing operations before income taxes(14.1)(28.4)(77.0)(35.0)
Income tax expense(0.1)(1.4)(3.8)(3.7)
Loss from continuing operations(14.2)(29.8)(80.8)(38.7)
(Loss) income from discontinued operations (including loss on sale of $200.3 million for the three months ended September 30, 2021 and loss on sale, net of $159.9 million and $39.3 million for the nine months ended September 30, 2021 and 2020, respectively)
(200.3)8.2 (149.9)(55.4)
Net loss(214.5)(21.6)(230.7)(94.1)
Net loss attributable to noncontrolling interest and redeemable noncontrolling interest2.6 4.3 7.9 6.8 
Net loss attributable to INNOVATE Corp.(211.9)(17.3)(222.8)(87.3)
Less: Preferred dividends and deemed dividends from conversions1.1 0.4 1.7 1.2 
Net loss attributable to common stock and participating preferred stockholders$(213.0)$(17.7)$(224.5)$(88.5)
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Depreciation and Amortization
Infrastructure
$7.4 $2.7 $13.1 $8.0 
Infrastructure recognized within cost of revenue
3.4 2.3 8.4 6.9 
Total Infrastructure10.8 5.0 21.5 14.9 
Life Sciences— — 0.1 0.1 
Spectrum1.4 1.7 4.3 5.1 
Non-operating Corporate0.1 0.1 0.1 0.1 
Total depreciation and amortization$12.3 $6.8 $26.0 $20.2 

Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Capital Expenditures (*)
Infrastructure
$6.1 $1.4 $11.6 $4.8 
Life Sciences— — 0.5 0.1 
Spectrum0.9 3.2 2.9 9.6 
Non-operating Corporate— — — 0.1 
Total$7.0 $4.6 $15.0 $14.6 

(*) The above capital expenditures exclude assets acquired under terms of capital lease and vendor financing obligations.
Segment Reporting for Long-term investments, Property and Equipment - Net and Assets
September 30,
2021		December 31,
2020
 
Investments
Infrastructure
$0.9 $0.9 
Life Sciences13.0 18.4 
Other36.0 36.1 
Total$49.9 $55.4 

September 30,
2021		December 31,
2020
 
Total Assets
Infrastructure
$917.7 $494.8 
Life Sciences29.3 21.4 
Spectrum199.8 213.6 
Other38.9 6,021.3 
Non-operating Corporate35.8 30.1 
Eliminations— (38.4)
Total$1,221.5 $6,742.8